Condition
Monoclonal Gammopathy of Renal Significance clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Monoclonal Gammopathy of Renal Significance clinical trials that are recruiting, at sites in 2 countries (most in United States (1), China (1)). By phase: Phase 2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Treatment for newly diagnosed monoclonal immunoglobulin deposition disease
This study is testing a new combination treatment for people who have just been diagnosed with monoclonal immunoglobulin deposition disease to see if it helps improve their blood health.
-
Combining CyBorD with Daratumumab for treating kidney disease related to monoclonal gammopathy
This study is testing a new treatment combining CyBorD and daratumumab to see if it can help people with kidney disease caused by monoclonal gammopathy feel better and improve their kidney function.
Related topics
Quick answers
How many Monoclonal Gammopathy of Renal Significance clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.